Aims Patients with heart failure experience a high burden of symptoms and physical
limitations, and poor quality of life. Dapagliflozin reduces heart failure hospitalization and …

Aims Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart
failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and …

Aims The effects of adding a sodium–glucose cotransporter 2 (SGLT2) inhibitor to a
mineralocorticoid receptor antagonist (MRA) or an angiotensin receptor–neprilysin inhibitor …

Background: Frailty is increasing in prevalence. Because patients with frailty are often
perceived to have a less favorable risk/benefit profile, they may be less likely to receive new …

Dapagliflozin was recently approved for use in adults with chronic heart failure with reduced
ejection fraction (HFrEF) with/without type 2 diabetes mellitus (T2DM). The objectives of this …

Aims This study aimed to explore the rapid effects of dapagliflozin in heart failure with
reduced ejection fraction (HFrEF). Methods and results We studied the functional …

Importance Dapagliflozin was shown to reduce the cardiovascular (CV) and kidney
outcomes in patients with type 2 diabetes. However, data are limited on the relationship of …

Importance Heart failure with reduced ejection fraction produces substantial morbidity,
mortality, and health care costs. Dapagliflozin is the first sodium-glucose cotransporter 2 …

Importance An initial decline in estimated glomerular filtration rate (eGFR) is expected after
initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed …

Background: Sodium-glucose cotransporter-2 inhibitors have emerged as a key
pharmacotherapy in heart failure (HF) with both reduced and preserved ejection fraction …